IDO1 and cancer: Nine inhibitors, namely, KDR, TGFB1, TGFBR1, CSF1R, HAVCR2, IDO1, IL10RB, CTLA4, and TIGIT, had a positive coexpression with LINC01614 in more than 25 cancers.